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the filamentous-actin severing protein Cofilin1 as
an exemplary target
Mads Gabrielsen1, Maike Schuldt1, June Munro1, Dagmara Borucka1, Jenifer Cameron1, Mark Baugh1,
Andrzej Mleczak2, Sergio Lilla1, Nicholas Morrice1 and Michael F Olson1*Abstract
Background: Cucurbitacins are a class of triterpenoid natural compounds with potent bioactivities that led to their
use as traditional remedies, and which continue to attract considerable attention as chemical biology tools and
potential therapeutics. One obvious target is the actin-cytoskeleton; treatment with cucurbitacins results in
cytoskeletal rearrangements that impact upon motility and cell morphology.
Findings: Cucurbitacin reacted with protein cysteine thiols as well as dithiothreitol, and we propose that the
cucurbitacin mechanism of action is through broad protein thiol modifications that could result in inhibition of
numerous protein targets. An example of such a target protein is Cofilin1, whose filamentous actin severing activity
is inhibited by cucurbitacin conjugation.
Conclusions: The implications of these results are that cucurbitacins are unlikely to be improved for selectivity by
medicinal chemistry and that their use as chemical biology probes to analyse the role of specific signalling
pathways should be undertaken with caution.
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The natural compound cucurbitacin triterpenes are a
group of structurally related compounds that give a variety
of plants and fungi their bitter taste as a defense against
being eaten [1]. Historically, cucurbitacin-producing
plants or extracts have been used as traditional remedies
for diseases such as cancer, inflammation and infection
[2]. More recently, cucurbitacins have attracted attention
because of several notable properties. Their potent cyto-
toxicity has led to numerous investigations on their poten-
tial utility as anti-cancer therapeutics [3-5]. In addition,
they have been used as chemical biology probes to explore
the biological roles of signalling pathways including
Jak/STAT3 [6,7], NF-κB [8], MAPK/ERK [9-11] and PI3-
kinase [10]. Cucurbitacin analogues also have marked
effects on the actin cytoskeleton, which in turn affects* Correspondence: m.olson@beatson.gla.ac.uk
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distribution, and reproduction in any mediumprocesses such as cell motility, tumour cell invasion and
metastasis [12-15]. In fact, the ability of cucurbitacin E to
inhibit filamentous actin (F-actin) depolymerisation led to
the suggestion that it would be useful as a tool to study
actin dynamics and actin-based processes in live cells [16].
With so many apparent biological activities, an import-
ant issue is how cucurbitacin compounds interact with
and consequently inhibit their protein targets. This ques-
tion is particularly important if a decision were made to
use medicinal chemistry to optimize cucurbitacin com-
pounds as anti-cancer therapeutics by improving their on-
target selectivity and potency while minimizing their
reported toxicities [17]. The mode of cucurbitacin binding
to protein targets is also an important issue if they are to
be used as chemical biology probes with confidence. One
attempt to address this question used in silico docking of
cucurbitacin B and E into the hydrophobic ligand-binding
pocket of B-Raf [11]. However, no direct physical mea-
surements were made to validate this hypothetical mech-
anism of action.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.biosignaling.com/content/11/1/58A previous attempt to characterize important cellular
targets of cucurbitacin used biotinylated cucurbitacin E
to purify interacting proteins from lysates of U937 hu-
man leukaemia cells and mass spectrometry (MS) for
protein identification, which led to the discovery of
Cofilin1 as a major interacting protein [12]. In this
study, we aimed to examine how cucurbitacin analogues
affect Cofilin1 activity and to identify the mechanism of
action. Using Cofilin1 as an exemplar, we sought to de-
termine if there might be specific or general modes used
by cucurbitacin compounds to interact with target pro-
teins, and by inference whether these compounds could
potentially be optimized for potency and selectivity.
Results and discussion
To determine how cucurbitacins affect cell viability and the
integrity of actin-based cytoskeletal structures, we tested
the activities of cucurbitacin D, E and I (Figure 1A) on cell
number and the fluorescence intensity of phalloidin-stained
F-actin. MCF7 human breast cancer cells were treated with
each cucurbitacin analogue at doses ranging from 0.3 nMA
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Figure 1 Cytotoxicity of cucurbitacin compounds. A) Chemical structur
cucurbitacin D, E and I. Viable MCF7 breast cancer cell numbers were dete
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phalloidin stained F-actin measured 4 h after cucurbitacin addition at doseto 10 μM for 3 days, then cell number was assessed by
counting 4’,6-diamidino-2-phenylindole (DAPI) stained nu-
clei by high content imaging analysis (Figure 1B). The ef-
fect of each cucurbitacin was similar, with a rank order of
potency of cucurbitacin E (EC50 = 4.7 nM) > cucurbitacin I
(EC50 = 10 nM) > cucurbitacin D (EC50 = 32 nM). Interest-
ingly, the −2.1 slope of the cucurbitacin E curve suggested
more than one target for the cytotoxic effects. The gross
effects of a range of cucurbitacin doses on the fluo-
rescence intensity of phalloidin-stained F-actin was
determined by measuring relative single cell phalloidin-
staining 4 hours after compound treatment (Figure 1C).
As with cell number, the effect of each cucurbitacin was
similar, with a rank order of potency; cucurbitacin I
(EC50 = 0.15 μM) > cucurbitacin D (EC50 = 0.35 μM) >
cucurbitacin E (EC50 = 0.56 μM). The 0.2 slope of the
cucurbitacin E curve again suggested more than one
cellular target for effects on phalloidin staining of F-
actin structures. These data indicate that cucurbitacins
are more effective at reducing cell number than for in-
ducing increased F-actin levels, suggesting that theacin E Cucurbitacin I
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http://www.biosignaling.com/content/11/1/58cytotoxic properties of these compounds may be largely
independent of their actions on cytoskeletal rearrange-
ments. Evidence from cucurbitacin E in particular sug-
gests that there may be multiple targets that decrease
cell proliferation and influence phalloidin staining of
F-actin.
We next determined how cucurbitacin treatment quali-
tatively affected F-actin structures. MCF7 cells were
treated with compound concentrations ranging from 1
nM to 1 μM for 4 hours, then after fixation, permea-
bilization and staining with DAPI and phalloidin, images
acquired by confocal microscopy (Figure 2). The lowest
concentration at which F-actin rearrangements were evi-
dent was 10 nM for cucurbitacin E and I, and 30 nM for
cucurbitacin D. F-actin was progressively reduced at cell-
cell interfaces and accumulated as large masses within the
cytoplasm with increasing concentrations of each cucur-
bitacin. Although the fluorescence intensity of phalloidin
stained F-actin was least potently affected by cucurbitacin E
(Figure 1C), qualitatively it appeared to have the greatest ef-
fect on inducing rearrangements (Figure 2).
The effect of cucurbitacin E on increasing cellular F-
actin has recently been attributed to its direct conjugation
with Cys257 on polymerized actin, but not monomeric
globular actin (G-actin) [16]. An additional actin regulator
identified as a potential target is the F-actin severing pro-
tein Cofilin1, which was isolated as a biotin-linked
cucurbitacin E interacting protein [12]. To determine how
cucurbitacin E might influence Cofilin1 F-actin severing
activity, we first determined a Cofilin1 concentration that
robustly reduced the level of F-actin that could be pelleted
from 16.8 μM total actin by high speed ultracentrifugation.
Actin was first polymerized in vitro, and then G-actin
(supernatant fraction S) fractionated from F-actin (pelleted
fraction P) by centrifugation at 150,000 X g for 1.5 hours
(Figure 3A). Increasing Cofilin1 concentrations revealed
an efficient effect of shifting actin from P to S fractions at
5 μM. To test the possibility that cucurbitacin E binds co-
valently to Cofilin1 as it does for actin [16], a range of
cucurbitacin E (CuE) concentrations at molar ratios up to
1:100 (relative to constant 5 μM Cofilin1) were incubated
with purified Cofilin1 protein for 16 h and examined for
their ability to induce a Cofilin1 mobility shift on 12% Bis-
Tris polyacrylamide gels. Although low cucurbitacin E
concentrations had no obvious effect, reduced Cofilin1
mobility was clearly evident at 1:50 and 1:100 molar ratios
(Figure 3B). Covalent modification of actin was similarly
achieved with a 1:100 molar ratio of actin protein to
cucurbitacin E [16]. To determine whether similar effects
were seen with additional cucurbitacin compounds, each
of three cucurbitacin compounds was incubated at 1:100
molar ratio with Cofilin1 that had been dialysed to remove
dithiothreitol (DTT). The mobility of Cofilin1 on 12% Bis-
Tris polyacrylamide gels was slowed by each cucurbitacin(Figure 3C, left panel), consistent with stable modification
of Cofilin1 by cucurbitacin compounds and increased
mass. The inclusion of 5 mM DTT blocked the mobility
shift induced by cucurbitacin compounds (Figure 3C, right
panel). However, there was no effect on the Cofilin1 mo-
bility shift if DTT was added after the incubation of
cucurbitacin E with Cofilin1 (Figure 3D). These results in-
dicate that Cofilin1 was modified by cucurbitacin com-
pounds to produce stable modifications that could not be
reversed by DTT.
The actin severing assay was used to determine whether
cucurbitacin E inhibited Cofilin1 F-actin severing activity
(Figure 3E). While DMSO vehicle control did not change
the S/P ratio, cucurbitacin E notably increased the pelleted
F-actin, consistent with a direct effect on inhibiting
depolymerisation [16]. The effect of Cofilin1 was to shift
actin to the monomeric S fraction, which was unaffected
by DMSO vehicle control. In contrast, treatment with
cucurbitacin E inhibited the actin severing activity of
Cofilin1, since the P fraction was significantly (p = 0.05)
increased relative to DMSO-treated Cofilin1 samples
(Figure 3F).
Mass spectrometry revealed that each cucurbitacin
treated sample had an increased mass (Figure 4A) co-
rresponding to the mass determined for Cofilin1
(19,714.5 Da) plus four times the mass of each cucur-
bitacin compound used (cucurbitacin D hypothetical/mea-
sured masses = 21781.3/21781.5; cucurbitacin E = 21941.3/
21940.9; cucurbitacin I = 21772.9/21772.2). Incubation
with 10 mM DTT for 3 h resulted in virtually complete re-
action of 100 μM cucurbitacin E with no loss of mass in
the product of the two reactants (hypothetical/measured
mass/charge = 709.308/709.309) (Figure 4B). To determine
the exact binding sites of cucurbitacin E, the treated
Cofilin1 was digested with trypsin, and the fragment sizes
determined by MS. Fragmentation by MS-MS of the pep-
tide containing Cys39 revealed that this was a site of
cucurbitacin E conjugation (Figure 4C). Fragments corre-
sponding to cucurbitacin E binding to peptides containing
cysteines 80 and 139 were also clearly identified, with
weaker evidence for binding of cucurbitacin E to cysteine
147 (data not shown).
As there was no loss of mass when cucurbitacin com-
pounds bound to Cofilin1 protein (Figure 4A) or DTT
reacted with cucurbitacin E (Figure 4B), it is likely that
the covalent binding is in the form of a thioether bond,
formed by the reactive α,β keto group on the cucur-
bitacin undergoing a Michaels addition to Cofilin1 cyst-
eine thiols (Figure 5A).
It is worth noting that the cucurbitacin-conjugated
Cofilin1 became extremely hydrophobic with a marked
propensity for non-specific binding to dialysis membranes
and columns, which resulted in complete loss of detect-
able cucurbitacin-conjugated Cofilin1 in some procedures.
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Figure 2 Dose dependent effects of cucurbitacin D, E and I on the actin cytoskeletal structures in MCF7 breast cancer cells. 4 hours
after cucurbitacin D (CuD), cucurbitacin E (CuE) or cucurbitacin I (CuI) treatment at doses from 1 nM to 1 μM, cells were fixed, permeabilized and
stained with Texas Red-conjugated phalloidin and DAPI. All images were acquired at identical magnification, but adjusted to produce images
with equivalent phalloidin intensities for visualization of actin structures.
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http://www.biosignaling.com/content/11/1/58Only by treating proteins directly in solution or following
extraction from polyacrylamide gels could any material be
obtained for analysis. Although Cofilin1 was identified
as a biotinylated-cucurbitacin E interacting protein incell lysates by mass spectrometry [12], no mass shift
was detected after incubation of purified Cofilin1 or
Gelsolin with cucurbitacin I [18], likely due to the
loss of cucurbitacin-conjugated protein because of their
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Figure 3 Cucurbitacin compounds react with Cofilin1 and inhibit activity. A) Ultracentrifugation was used to separate actin into soluble (S)
monomeric actin and pellet (P) F-actin high speed fractions. Coomassie staining revealed that the addition of increasing Cofilin1 concentrations
shifted actin from P to S fractions, indicating increased actin severing. The 5 μM Cofilin1 concentration was used for subsequent experiments. B)
Cofilin1 at 5 μM was incubated with cucurbitacin E (CuE) at the indicated molar ratios. Protein mobility was slowed at 1:50 and 1:100 ratios. C)
Incubation with cucurbitacin D (CuD), E or I (CuI) slowed Cofilin1 electrophoretic mobility, while co-incubation with 5 mM DTT blocked this effect
on Cofilin1 mobility. D) Mobility shift of Cofilin1 could not be blocked if 5 mM DTT was added after incubation with cucurbitacin E. E) Actin
partitioning into soluble (S) and pellet (P) fractions after ultracentrifugation was used to determine how actin-severing by Cofilin1 was affected by
Cucurbitacin E. F) Quantification of the proportions of soluble (S) versus pelleted (P) actin fractions following ultracentrifugation for the indicated
conditions. Cofilin1 increased the soluble monomeric actin fraction relative to control. Cucurbitacin E significantly (p = 0.05) inhibited
Cofilin1-mediated actin severing relative to control DMSO vehicle when the P fractions were compared by Student’s t-test (n = 3).
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http://www.biosignaling.com/content/11/1/58hydrophobicity. This property has also likely hampered ef-
forts to identify additional cucurbitacin binding proteins.
To determine whether Cofilin1 inhibition would be suf-
ficient to induce the effects on F-actin structures observedfollowing cucurbitacin treatment (Figure 2), we used
siRNA to knockdown Cofilin1. Western blotting showed
effective suppression of Cofilin1 protein in MCF7 cells
transfected with Cofilin1 siRNA but not non-targeting
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Figure 4 Mass spectrometry reveals conjugation of cucurbitacin to thiols. A) Mass of Cofilin1 protein alone or following incubation with
cucurbitacin D, E or I as indicated, as determined by mass spectrometry. B) Mass/charge determination of cucurbitacin E that had been incubated
with DTT reveals that a reaction product that conserves mass had been formed, consistent with a Michaels addition reaction. C) MS-MS spectra
of the tryptic peptide containing Cys39, modified (left) and unmodified (right) with cucurbitacin E. Correspondent mass of the precursors
peptides are indicated in the figures, and highlight that the same peptide sequence has a difference in molecular weight, corresponding to one
cucurbitacin E molecule (556.3 Da).
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http://www.biosignaling.com/content/11/1/58control (NTC) siRNA (Figure 6A). Staining transfected
cells revealed that Cofilin1 knockdown was not sufficient
to reproduce the effects on F-actin structures induced by
cucurbitacins (Figure 6B), consistent with the conclusion
that there are multiple proteins targets for these
compounds.
The sub-cellular localization of Cofilin1 was examined
in MCF7 cells treated with DMSO vehicle or cucurbitacin
E at 3 nM, 30 nM or 300 nM for 4 h. Fixed cells were
stained for F-actin with phalloidin or Cofilin1 using the
antibody validated in Figure 6. Although F-actin was found
in large perinuclear masses at 30 nM and 300 nM
cucurbitacin E, Cofilin1 distribution did not vary greatly
from its mixed cytoplasmic/nuclear distribution (Figure 7).
Our results clearly show that cucurbitacin compounds
bind covalently to the cysteines present in Cofilin1, andthat this binding inhibits the ability of Cofilin1 to sever F-
actin. By modelling the addition of cucurbitacin E to
Cys139 on our recently solved crystal structure of hu-
man Cofilin1 (depicted with space filling; PDB ID 4BEX
[19]) that was modelled with associated actin (ribbon)
based on the C-terminal Cofilin-like domain of mouse
twinfilin (Twf-C) in complex with a single unit of actin
(PDB ID 3DAW) [20], it becomes apparent that the con-
jugated cucurbitacin would disrupt the interface between
Cofilin1 and actin (Figure 5B). A similar conjugation to
Cys147 would also likely lead to a clash with F-actin that
would inhibit actin-severing. The increased hydrophobi-
city of the surface of cucurbitacin-modified Cofilin1 would
also likely interfere with binding to F-actin. Although
Cys39 and Cys80 are positioned away from the Cofilin1-
actin interface, their relatively buried positions could result
AB
Figure 5 Model of cucurbitacin binding to Cofilin1. A) Reaction of cucurbitacin E (Michaels acceptor group in red) with nucleophilic thiol,
producing a product that conserves mass. B) Crystal structure of human Cofilin1 (space filled) modelled with associated actin (ribbon), based on
the C-terminal Cofilin-like domain of mouse twinfilin (Twf-C) in complex with actin. Cucurbitacin E (sticks) is modelled as conjugated to Cys139,
with its potential rotational space illustrated by the transparent yellow sphere. The size of cucurbitacin E at this position would likely clash with
actin, resulting in reduced actin-severing activity.
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http://www.biosignaling.com/content/11/1/58in disruption of protein folding if conjugated to the bulky
cucurbitacin molecules, similar to the cucurbitacin-
induced structural rearrangements observed for human
serum albumin [21], which could also inhibit F-actin sev-
ering activity.
In addition to cucurbitacin E binding to thiols on F-
actin [16], Cofilin1 and DTT, cucurbitacin B was reported
to form adducts with thiol-containing N-acetylcysteine(NAC) and glutathione, but not thiol-free vitamin C or as-
corbic acid [22]. Although NAC blocked the cytotoxicity
of cucurbitacin B, vitamin C and ascorbic acid did not
[22]. These results suggest that rather than inhibiting the
effect of cucurbitacin B through anti-oxidant properties,
which NAC, vitamin C and ascorbic acid all share, the in-
hibitory effect of NAC is more likely to be a consequence
of its direct conjugation with cucurbitacin B. In fact, the
AB
Figure 6 Cofilin1 knockdown does not affect F-actin structures. A) Western blotting of MCF7 lysates indicating efficient siRNA-mediated
Cofilin1 knockdown but no effect of non-targeting control (NTC) siRNA. B) Immunofluorescence of F-actin and Cofilin1 following transfection
with NTC or Cofilin1 siRNA revealed that Cofilin1 inhibition is not sufficient to induce significant F-actin changes.
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http://www.biosignaling.com/content/11/1/58ability of the reactive oxygen scavenging NAC to reverse
the effects of cucurbitacin has widely been interpreted as
evidence that generation of reactive oxygen species is part
of its mechanism of action [23]. Our alternative interpret-
ation is that the neutralization of the biological effects of
cucurbitacin compounds is via direct conjugation with
NAC in tissue culture medium or in cells, meaning that
all experiments in which NAC and cucurbitacins have
been combined should be interpreted with caution.
Conclusions
Although cucurbitacin compounds have been proposed to
be potential anti-cancer drugs and are used to inhibit spe-
cific signal transduction pathways, the results of this study
and others [16,23] support the conclusion that cucur-
bitacins non-specifically bind protein targets by forming
thioether bonds via a Michaels-type addition. This would
allow cucurbitacins to be conjugated with a broad array of
potential protein targets, many of which would be inhi-
bited or disrupted as a consequence. As a result, their
value as chemical biology probes is limited and must beconfirmed by independent means. For example, although
cucurbitacin I was reported to be a selective inhibitor of
Jak/STAT3 signalling [6] and has been used to test the in-
volvement of this pathway in various processes, the ability
of cucurbitacin I to activate Rac1 was not replicated by
Jak2 or Stat3 knockdown by siRNA [24]. The findings
in this study also indicate that the binding mode of
cucurbitacin compounds to protein targets means that
optimization for selectivity would be unlikely to work,
which would make it very difficult to minimize toxicities
or improve the therapeutic window for future clinical de-
velopment. Optimistically, alternative ways that their po-
tential therapeutic utility could be improved in the future
would be through targeted delivery to tumour cells, for ex-
ample through antibody-conjugation or incorporation in
liposome microparticles [25].
Methods
Cell culture
MCF-7 human breast cancer cells were grown in
Dulbecco’s modified eagle’s medium (Gibco) with 10%
Figure 7 Subcellular localization of Cofilin1. Increasing concentrations of cucurbitacin E (CuE) from 3 nM to 300 nM were incubated with
MCF7 cells for 4 h, followed by fixation and staining for F-actin structures and Cofilin1 subcellular localization. Despite evident effects on F-actin
and cell morphology at 30 nM and 300 nM cucurbitacin E, Cofilin1 distribution was not observably changed.
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http://www.biosignaling.com/content/11/1/58fetal bovine serum (PAA) at 37°C and 5% CO2. Transfec-
tions with non-targeting control siRNA D001810-01-05
and human Cofilin1 siRNA J012707-05 (Abgene) were
performed as described in [26].
Cytotoxicity and actin-phalloidin fluorescence assays
MCF-7 cells were trypsinized and to each well of Greiner
black-walled, clear bottomed 96-well plates, 100 μl of cell
suspension (2,000 cells for cytotoxicity, 5,000 cells for
phalloidin staining) was added. Plates were left to stand in
the hood for 10 minutes to aid uniform cell attachmentprior to placing in CO2 incubator. After 24 hours attach-
ment, 100 μl of media containing DMSO vehicle or cu-
curbitacin compounds was added to the wells. For
cytotoxicity, cells were cultured for a further 3 days and
then after fixation with 4% paraformaldehyde for 15 mi-
nutes at room temperature and DAPI staining of cell nu-
clei, cell number was assessed using an Operetta high
content imaging system (Perkin Elmer). For actin-
phalloidin fluorescence measurements, cells were cul-
tured for 4 hours after treatment. After fixation with 4%
paraformaldehyde for 15 minutes at room temperature,
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http://www.biosignaling.com/content/11/1/58permeabilization with 0.25% (v/v) Triton X-100 and
staining of actin structures with Texas Red-conjugated
Phalloidin (2 μg/mL), fluorescence intensity was mea-
sured using an Operetta high content imaging system.
Imaging of actin structures was done using a Zeiss 710
confocal microscope.
Binding of cucurbitacin to Cofilin1
Cofilin1 was expressed and purified as described previ-
ously [27]. Binding of cucurbitacin to Cofilin1 was
achieved by incubating 5 μM Cofilin1 with a dose range
from 5 μM to 500 μM cucurbitacin (solubilised in 100%
DMSO) or an equivalent volume of DMSO at 4°C over-
night. Cucurbitacin binding to Cofilin1 was analysed on
12% Bis-Tris SDS-PAGE gels and SimplyBlue (Invitrogen)
stained gels scanned on a LiCor Odyssey.
Mass-spectroscopy analysis
5 μmol Cofilin1 was incubated with 0.5 mM Cucurbitacin
E, separated by SDS-PAGE, stained with colloidal
Coomassie Blue and digested with trypsin. The digests
were analysed by LC-MS using an AB-Sciex 5600
TripleTOF mass spectrometer coupled to an Eksigent 2D
Ultra HPLC system fitted with a 150 × 0.075 mm C18
packed emitter (New Objective). Digests were loaded in
2% acetonitrile/0.1% formic acid (Buffer A) and then
eluted with a linear gradient of buffer B (100% aceto-
nitrile/0.1% formic acid) at 300 nL/min. LC-MS data was
searched using Mascot 2.4 run on a local server against
SwissProt allowing for trypsin cleavages and cysteine mod-
ifications of oxidation and cucurbitacin isoforms. To de-
termine the intact mass of cucurbitacin modified Cofilin1,
complexes were diluted into 25% acetonitrile/0.5% formic
acid and separated on an Eskigent 150 × 0.3 mm
ChromXP C18CL column. The mass spectra were ac-
quired on the 5600 TripleTOF with the intact protein
script activated (AB-Sciex) from m/z 600–2000 and spec-
tra were deconvoluted using BioAnalyst 1.5 to calculate
the exact mass of the protein complex.
100 μM Cucurbitacin E was incubated plus or minus
10 mM DTT in 50 mM TEAB pH 8 for 3 h at room
temperature and diluted 1:10 with 50% acetonitrile/0.1%
formic acid. Samples were analysed by MS on 5600
TripleTOF by infusing at 1 μl/min and data was ac-
quired in negative ion mode (TOF-MS and MS-MS).
F-actin depolymerization assay
The Actin Binding Protein Biochem Kit with Non-Muscle
Actin (Cytoskeleton) was used according to manufac-
turer’s instructions. Aliquots of actin polymerization buf-
fer and ATP were rapidly defrosted in a room temperature
water bath and kept on ice. Cofilin1 samples were
centrifuged for 1 h at 100,000 X g at 4°C, supernatants
taken and kept on ice as test protein stocks. General actinbuffer was supplemented with 0.2 mM final ATP. One
250 μg aliquot of actin was diluted to 1 mg/ml with 225 μl
of ATP-supplemented general actin buffer, mixed to en-
sure complete re-suspension and left on ice for 30 min.
25 μl of actin polymerization buffer was pipetted into the
actin protein and mixed well. The actin was incubated at
room temperature for 1 h and kept as F-actin stock at
21 μM actin. All tubes were incubated at room tempe-
rature for 30 min. Afterwards the tubes were centrifuged
at 150,000 X g for 1.5 h at 24°C. Supernatants were re-
moved and kept on ice. To each tube 10 μl of 5×
Laemmli reducing sample buffer was added. The pellets
were re-suspended in 30 μl water by mixing for 2 min,
leaving on ice for 10 min and repeated mixing. The
samples were transferred into tubes and supplemented
with 30 μl 2× Laemmli reducing-sample buffer. The
samples were frozen at −20°C until further analysis by
SDS-PAGE. Quantification was performed with a Licor
Odyssey by scanning the fluorescence intensity of
SimplyBlue (Invitrogen) stained bands at 700 nm.
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